Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 9/20 | 0.40 |
| ▸ | THRA | P10827 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479192 | 0.87 | KMT2A (0.50) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL5566665 | 0.80 | MEN1 (0.58) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL5561613 | 0.79 | MEN1 (0.52) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL7909905 | 0.76 | KMT2A (0.58) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL7472949 | 0.76 | MEN1 (0.51) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL7917755 | 0.75 | MEN1 (0.53) | P2RX7MEN1NR1I2KMT2ATHRB | |
| SCHEMBL1412972 | 0.74 | P2RX7 (0.65) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL1412866 | 0.74 | P2RX7 (0.64) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL10512600 | 0.73 | HIF1A (0.50) | P2RX7ABCB11MEN1NR1I2KMT2A | |
| SCHEMBL6701530 | 0.72 | MEN1 (0.45) | P2RX7ABCB11MEN1NR1I2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | P2RX7 316/4885ABCB11 3042/4885MEN1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.